{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T18:10:44Z","timestamp":1778177444017,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018504","name":"Nipro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018504","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.eprac.2020.12.009","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T13:45:16Z","timestamp":1609422316000},"page":"586-593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Real-World Evidence of the Incidence of and Risk Factors for Type 1 Diabetes Mellitus and Hypothyroidism as Immune-Related Adverse Events Associated With Programmed Cell Death-1 Inhibitors"],"prefix":"10.1016","volume":"27","author":[{"given":"Koki","family":"Shimada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4876-446X","authenticated-orcid":false,"given":"Eiji","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-6191","authenticated-orcid":false,"given":"Hiraku","family":"Kumamaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiori","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6902-2342","authenticated-orcid":false,"given":"Nao","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8931-5927","authenticated-orcid":false,"given":"Norimichi","family":"Hirahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Miyachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5S","key":"10.1016\/j.eprac.2020.12.009_bib1","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2018.0047","article-title":"New NCCN guidelines: recognition and management of immunotherapy-related toxicity","volume":"16","author":"Thompson","year":"2018","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"17","key":"10.1016\/j.eprac.2020.12.009_bib2","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.eprac.2020.12.009_bib3","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.eprac.2020.12.009_bib4","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1507\/endocrj.EJ19-0163","article-title":"Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society","volume":"66","author":"Arima","year":"2019","journal-title":"Endocr J"},{"issue":"1","key":"10.1016\/j.eprac.2020.12.009_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.eprac.2020.12.009_bib8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s13340-018-0362-2","article-title":"Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy","volume":"10","author":"Baden","year":"2019","journal-title":"Diabetol Int"},{"issue":"4","key":"10.1016\/j.eprac.2020.12.009_bib9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.eprac.2020.12.009_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.eprac.2020.12.009_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2020.12.009_bib12","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1172\/JCI129197","article-title":"Opportunities and challenges in using real-world data for health care","volume":"130","author":"Rudrapatna","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.eprac.2020.12.009_bib13","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/bcp.12474","article-title":"Adverse drug reactions\u2014examples of detection of rare events using databases","volume":"80","author":"Chan","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.eprac.2020.12.009_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"5","key":"10.1016\/j.eprac.2020.12.009_bib17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/cts.12644","article-title":"Does industry-conducted all-case surveillance of newly approved oncology drugs contribute to the revision of package inserts in Japan?","volume":"12","author":"Suzuki","year":"2019","journal-title":"Clin Transl Sci"},{"issue":"9796","key":"10.1016\/j.eprac.2020.12.009_bib18","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S0140-6736(11)60828-3","article-title":"Japanese universal health coverage: evolution, achievements, and challenges","volume":"378","author":"Ikegami","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eprac.2020.12.009_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/1536867X1701700110","article-title":"The estimation and modelling of cause-specific cumulative incidence functions using time-dependent weights","volume":"17","author":"Lambert","year":"2017","journal-title":"Stata J"},{"key":"10.1016\/j.eprac.2020.12.009_bib20","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.eprac.2020.12.009_bib21","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.eprac.2020.12.009_bib22","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.eprac.2020.12.009_bib23","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2020.12.009_bib24","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes","volume":"104","author":"Tsang","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2020.12.009_bib25","doi-asserted-by":"crossref","first-page":"k793","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.eprac.2020.12.009_bib26","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US food and drug administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"4","key":"10.1016\/j.eprac.2020.12.009_bib27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy\u2014immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2020.12.009_bib29","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.eprac.2020.12.009_bib30","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.eprac.2020.12.009_bib31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2020.12.009_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrendo.2014.186","article-title":"Thyroid transcription factors in development, differentiation and disease","volume":"11","author":"Fern\u00e1ndez","year":"2014","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2020.12.009_bib33","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.21037\/jtd.2019.04.102","article-title":"Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer","volume":"11","author":"Koyama","year":"2019","journal-title":"J\u00a0Thorac Dis"},{"issue":"2","key":"10.1016\/j.eprac.2020.12.009_bib34","first-page":"86","article-title":"A\u00a0review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20484320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20484320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:11:01Z","timestamp":1761516661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20484320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1530891X20484320"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2020.12.009","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Evidence of the Incidence of and Risk Factors for Type 1 Diabetes Mellitus and Hypothyroidism as Immune-Related Adverse Events Associated With Programmed Cell Death-1 Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2020.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}